Status:
UNKNOWN
The Prognostic Significance of Fibrosis Detection in Cardiomyopathy
Lead Sponsor:
Royal Brompton & Harefield NHS Foundation Trust
Conditions:
Cardiomyopathy
Coronary Artery Disease
Eligibility:
All Genders
18-80 years
Brief Summary
The presence of scar within heart muscle can act as a substrate for abnormal rhythm problems and lead to the developement of heart failure Clinical significance Correlation with biomarkers and geneti...
Detailed Description
Patients will undergo cardiovascular magnetic resonance (CMR) to include measurement of left ventricular volumes, ejection fraction, detection of inflammation (via STIR sequences) where appropriate, e...
Eligibility Criteria
Inclusion
- presence of an ischaemic or non-ischaemic cardiomyopathic process
- no contraindication to contrast enhanced CMR
- GFR \>30
Exclusion
- ESRF
- Contraindication to CM R
Key Trial Info
Start Date :
January 1 2000
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2025
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT00930735
Start Date
January 1 2000
End Date
July 1 2025
Last Update
April 23 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Brompton Hospital
London, United Kingdom, SW3 6NP